FDA Approves Merck’s Keytruda (pembrolizumab) Combined With Trastuzumab and Chemotherapy as First-line Treatment in Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
KENILWORTH, N.J.–(BUSINESS WIRE) May 5, 2021– Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced
Read more